KRAS and non-small cell lung carcinoma: Despite not showing significant response rates or survival outcomes compared to docetaxel in the second-line treatment of NSCLC, trametinib was evaluated in association with sotorasib in KRAS G12C-mutated NSCLC and CRC [75].